Clinlcal study of sunitinib in the treatment of patients with advanced renal cell carcinoma
-
摘要: 目的：探讨苹果酸舒尼替尼对晚期肾细胞癌治疗的安全性和有效性。方法：晚期肾细胞癌患者22例，男18例，女4例，平均年龄56岁，均为转移性或难以手术的肾细胞癌患者。采用舒尼替尼治疗，其中18例为一线治疗，4例为二线治疗。均为单一服药，口服50 mg/d，每4周停药2周者16例；口服37.5 mg/d，连续服药者6例。持续用药至肿瘤进展或出现不可耐受的并发症。以6周为1个治疗周期，至少每2个治疗周期进行疗效评价。结果：1例患者服药不足2周期内死亡，可评价病例21例。部分缓解6例（28.6%），疾病稳定13例（61.9%），疾病进展2例（9.5%），无完全缓解病例。常见的不良反应包括手足皮肤反应、皮疹、疲劳乏力、骨髓抑制、味觉变化等。结论：舒尼替尼治疗晚期肾癌患者效果确切，不良反应多数可控制，但对于KPS评分较低，一般情况差，肿瘤负荷大的患者，运用时需慎重。Abstract: Objective: To evaluate the efficacy and safety of sunitinib for patient with advanced renal cell carcinoma.Method: The clinical data of 22 patient with advanced renal cell carcinoma reviewed. 18 were males and 4 were females, the average age was 56 years. All the patient were diagnosised as advanced renal carcinoma. Sunitinib was used as first-line treatment for 18 cases, while second-line treatment for 4 cases. 16 patients took 50 mg orally once daily for 4 weeks, followed by 2 weeks off, and 6 patients took 37.5 mg daily continuously, until intolerance or disease progression occurred. Every 6 weeks was a cycle and imaging examination scan was used to evaluate the efficacy every 2 cycle.Result: One patient died before 2 cycle. 21 patient could be evaluated the efficacy. CR 0 case, PR 6 cases, SD 13 cases, PD 2 cases. The common side effects included hand-foot skin reaction, rash, lassitude, arrest of bone marrow, taste sense, etc.Conclusion: Sunitinib has definitive efficacy for patients with advanced renal cell carcinoma. Most side effects were controllable. But it should be cautious when using sunitinib for patient with low Karnofsky score, huge tumor load and general circumstance bad.
-
Key words:
- renal cell carcinoma /
- neoplasm metastasis /
- sunitinib
-
-
[1] 顾方六. 肾肿瘤[M]. 吴阶平主编. 吴阶平泌尿外科学. 济南:山东科学技术出版社, 2004:889-917.
[2] Cohen H T, McGovern F J. Renal-cell carcinoma[J]. N Engl J Med, 2005, 353:2477-2490.
[3] Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma:insights into the treatment, efficacy and safety[J]. Jpn J Clin Oncol, 2010, 40:194-202.
[4] Motzer R J, Hutson T E, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27:3584-3590.
[5] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45:228-247.
[6] Wood L. First-line therapy with sunitinib in advanced renal cell carcinoma:interpretation of the overall survival data from ASCO 2008[J]. Curr Oncol, 2009, 16 Suppl 1:S24-S26.
[7] Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib[J]. Ann Oncol, 2011, 22:794-800.
[8] Paule B, Brion N. Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases[J]. Anticancer Res, 2010, 30:5165-5168.
[9] O'Brien M F, Russo P, Motzer R J. Sunitinib therapy in renal cell carcinoma[J]. BJU Int, 2008, 101:1339-1342.
-
计量
- 文章访问数: 50
- PDF下载数: 103
- 施引文献: 0
下载: